TrialBreast cancer research and treatment2025

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.

Vishnu Prasath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.